We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App





Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas

By LabMedica International staff writers
Posted on 30 Jul 2024

Thermo Fisher Scientific Inc. More...

(Waltham, MA; USA) is showcasing its broad diagnostics portfolio and hosting a series of customer-led workshops and presentations that highlight industry developments and the company’s latest innovations at ADLM 2024. The company’s conference booth is designed as a “Story Tunnel” to lead visitors along a journey of research and clinical solutions impacting patient care across oncology, infectious disease, women’s health, toxicology, allergy and autoimmune diseases, and transplant and protein diagnostics.

Supporting innovation in protein diagnostics, Thermo Fisher is demonstrating the Optilite Analyzer, along with providing an overview of the Freelite assays, which received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to evaluate monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. The integration of liquid chromatography mass spectrometry (LC-MS) into the healthcare setting also continues, as demonstrated by the recent launch of the Thermo Scientific Stellar mass spectrometer, an LC-MS solution that combines fast throughput and high sensitivity to advance clinical research. The system powers the conversion of scientific discoveries into clinical research applications.

Recognized as one of TIME’s best inventions and the first immunoassays to receive FDA breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, Thermo Fisher’s test is also being featured in the ‘Story Tunnel’ booth where visitors can learn how the novel biomarkers are impacting treatment decisions for a growing number of mothers and their unborn children. Early test adopter Dr. Sarosh Rana, professor of Obstetrics and Gynecology and Section Chief of Maternal-Fetal Medicine at the University of Chicago, is a key opinion leader attending ADLM sharing her insights on the risks of preeclampsia and how Thermo Fisher’s assays are supporting maternal health at her hospital.

Following its exclusive distribution agreement with Aesku Group, Thermo Fisher now offers Aesku’s portfolio of FDA-cleared IFA products, automated instruments, like the Helios HTC and software, in addition to EliA assays, which help provide unparalleled focus on automation and workflow efficiency to support earlier diagnosis and improve care for patients with autoimmune conditions. Thermo Fisher is showcasing these capabilities in a presentation titled, Automated IFA now available through Thermo Fisher in the US. Enabling faster and more accurate diagnoses for patients with complex autoimmune conditions, the Helios IFA System together with the EliA portfolio, run on Phadia Laboratory Systems, meets the evolving needs of laboratories and allows for more efficient workflows by providing the most comprehensive suite of automated diagnostic systems and methodologies available in the U.S. market.

The World Health Organization (WHO) estimates that about 10% of people initiating antiretroviral treatment (ART) globally carry drug-resistant HIV strains. Stephen Williams, PhD, clinical director at Thermo Fisher Scientific, is hosting a workshop titled, Testing for HIV Integrase Inhibitor Resistance: 2024 and Beyond. The discussion features perspectives from key opinion leaders in the HIV-DR field to discuss the current state of drug resistance globally and new challenges related to the detection and monitoring of HIV-DR in the era of integrase strand transfer inhibitors. The antibiotic stewardship (ABS) landscape continues to evolve, which is driving the way ABS committees operate. To help shed light on this evolution, Dr. Michael Broyles, Pharm D, director of medical affairs at Thermo Fisher, is leading an industry workshop to discuss a path forward to help meet changing requirements for ABS and improve clinical outcomes during his presentation titled, Navigating Antibiotic Stewardship Regulations with Procalcitonin.

“As the demands of the healthcare industry evolve, we continuously collaborate with our customers to provide advanced and reliable diagnostics solutions to help accelerate the development of new therapies and disease identification, ultimately supporting more informed treatment decisions for patients,” said Puneet Sarin, senior vice president, and president, specialty diagnostics at Thermo Fisher. “With our product innovation, we’re also strengthening our distribution channels to ensure our leading-edge solutions are accessible to those who need them. We are driven by our Mission to enable our customers to make the world healthier, cleaner, and safer, supporting our customers in the moments that matter most.”

Related Links:
Thermo Fisher Scientific Inc.


Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.